Clinical trials: Schizophrenia and Disorders With Psychotic Features
Schizophrenia, Bipolar I Disorder
Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
Study to compare the pharmacokinetics and pharmacodynamics of VHX-896 and iloperidone and evaluate the safety and tolerability of VHX-896 and iloperidone in patients with schizophrenia or bipolar I disorder under steady state…
- Trial name
- NCT06494397
- Testing
- VHX-896 and iloperidone, Iloperidone and VHX-896
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Vanda Pharmaceuticals
Psychosis
Hippocampal Memory Circuits in Delusions
This study will investigate dentate gyrus (DG) and hippocampal CA3 sub field function, using the pattern separation paradigm, as reflected by the difference in brain activation in response to same-as-previously- seen (OLD) vs.
- Trial name
- NCT03822910
- Testing
- Pattern Separation Paradigm, Sequential Associative Mismatch Paradigm, Encoding Plasticity Paradigm
- Where
- 3 sites in United States, China
- Volunteers
- 212 people
- Sponsor
- NYU Langone Health
Schizophrenia, Extrapyramidal Syndrome
Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism
We initiate a study with research grant from department of health and Taoyuan mental hospital and choose risperidone and olanzapine as study medications.
- Trial name
- NCT00331825
- Testing
- Risperidone and Olanzapine
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Schizophrenia
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with…
- Trial name
- NCT07038876
- Testing
- ML-007C-MA BID, ML-007C-MA QD
- Where
- 24 sites in United States
- Volunteers
- 307 people
- Sponsor
- MapLight Therapeutics
Schizophrenia
The Efficacy of REHACOP Program in Schizophrenia
This study examined the efficacy of an integrative cognitive remediation program (REHACOP) to improve cognition, social cognition, clinical symptoms and functional outcome in patients with schizophrenia.
- Trial name
- CSrehacopSZ (NCT02796417)
- Testing
- REHACOP, Occupational activities
- Where
- Spain
- Volunteers
- 111 people
- Sponsor
- University of Deusto
Psychosis, Substance Use
Families With Substance Use and Psychosis: A Pilot Study
The purpose of this study is to develop and evaluate an intervention that adapts Community Reinforcement and Family Training (CRAFT) for families experiencing first episode psychosis and substance use delivered via telemedicine…
- Conditions
- Psychosis, Substance Use, Substance Use Disorders, Family
- Trial name
- NCT04284813
- Testing
- CRAFT-FT
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Negative Symptoms in Schizophrenia, Schizophrenia Disorders
40 Hz Visual Stimulation as an Intervention in Schizophrenia
In schizophrenia, an abnormal reduction in neuronal gamma oscillations (30-100 Hz) is associated with negative symptoms such as cognitive dysfunction.
- Conditions
- Negative Symptoms in Schizophrenia, Schizophrenia Disorders, Schizoaffective Disorder
- Trial name
- GammaSZ (NCT06907420)
- Testing
- Visual stimulation
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Technical University of Munich
Tardive Dyskinesia
Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia
The aim of the study was to evaluate the efficacy, safety, and cognitive function of transcranial direct current stimulation (tDCS) in chronic schizophrenia patients with tardive dyskinesia (TD).
- Trial name
- NCT03497013
- Testing
- Active tDCS
- Where
- 2 sites in China
- Volunteers
- 64 people
- Sponsor
- Suzhou Psychiatric Hospital
Schizophrenia, Psychotic Disorders
Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up
This study compares the efficacy and effectiveness of two of the second-generation antipsychotics (SGAs) most used in our society in the treatment of schizophrenia (Aripiprazole and Risperidone) and the investigators do within an…
- Conditions
- Schizophrenia, Psychotic Disorders, Psychosis
- Trial name
- PAFIP3_3Y (NCT03090503)
- Testing
- Aripiprazole, Risperidone
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Fundación Marques de Valdecilla
Bipolar Disorder, Schizophrenia
Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine
The purpose of this study is to determine if taking green tea capsules can help prevent weight gain in patients that start therapy with Zyprexa® (olanzapine).
- Trial name
- NCT00934908
- Testing
- Green Tea
- Where
- United States
- Sponsor
- Medical University of South Carolina
Schizophrenia, Major Depressive Disorder
General Practice Research Database Seroquel XR Safety Study
The main objective of this observational study is to characterize new users of quetiapine XR as well as new users of other study drugs (i.e.
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar Disorder
- Trial name
- GPRD SeroquelS (NCT01447082)
- Where
- Switzerland
- Volunteers
- 37,372 people
- Sponsor
- AstraZeneca
Schizophrenia
Digital Voice Analysis in Patients With Schizophrenia
There is a differences in voice frequency of schizophrenic patients compared to patients with other mental diseases and compared to mentally healthy people.
- Trial name
- NCT00524979
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BeerYaakov Mental Health Center
Schizophrenia
Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Negative Symptoms in Schizophrenia
The purpose of this study is to determine whether the iTBS is an effective treatment of the negative symptoms of schizophrenia.
- Trial name
- NCT00875498
- Testing
- active iTBS
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Hôpital le Vinatier
Schizophrenia
Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy (effectiveness of drug) and safety of the antipsychotic paliperidone ER compared to another antipsychotic, quetiapine, and to placebo in patients who are acutely ill with…
- Trial name
- NCT00334126
- Volunteers
- 399 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Fibromyalgia, Schizophrenia
Soft Tissue Tenderness and Fibromyalgia Among Schizophrenia Patients.
Numerous studies reported on comorbidity of fibromyalgia and psychiatric disorders. Approximately 30% of patients with fibromyalgia have major depression at the time of diagnosis; the lifetime prevalence of depression is 74% and…
- Trial name
- NCT05328518
- Where
- Israel
- Volunteers
- 286 people
- Sponsor
- HaEmek Medical Center, Israel
Schizophrenia, Schizoaffective Disorder
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
The purpose of this study was to determine whether patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who also have metabolic syndrome have a larger decrease in fasting non-high density lipoprotein…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
- Trial name
- NCT00857818
- Testing
- Aripiprazole, Oanzapine, risperidone, or quetiapine
- Where
- 14 sites in Canada
- Volunteers
- 64 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizoaffective Disorder
Synergy Between Physical Activity and Outdoor Green Environments to Reduce the Intensity of Negative Symptoms in Schizophrenia.
Physical activity appears to be a novel and original adjunctive therapeutic approach in the management of patients with schizophrenia.
- Trial name
- SAPIN (NCT07058389)
- Testing
- 8-week outdoor physical activity program, 8-week indoor physical activity program
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Schizophrenia
The Effect of a Community-based LAT-treated Management Model on the Violence Risk of Patients With Schizophrenia
This is a 49 weeks open-label randomized controlled study. Patients with schizophrenia and violence risk will be enrolled in the study.
- Trial name
- NCT03434210
- Testing
- LAT-treated Community Model, care as usual
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Yi Li MD, PhD
Schizophrenia
L-arginine in Treatment as Usual in Schizophrenia
STUDY OBJECTIVES: To determine whether the addition of L-arginine to treatment as usual (TAU) in schizophrenia further improves and enhances therapeutic efficacy (positive, negative and depressive symptoms) and effectiveness of…
- Trial name
- NCT00718510
- Testing
- L-Arginine
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- University of Alberta
Schizophrenia, Schizoaffective Disorder
Work Activity Augmented by Cognitive Rehabilitation for Schizophrenia
This research investigates the benefits of productive activity and cognitive rehabilitation for patients with schizophrenia. Key questions are: 1.
- Trial name
- NCT00430560
- Testing
- cognitive rehabilitation, work therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- VA Office of Research and Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.